Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Human Ductal Carcinoma In Situ: from the Eyes of a Beholder.

Herschkowitz JI, Behbod F.

J Mammary Gland Biol Neoplasia. 2018 Dec;23(4):189-190. doi: 10.1007/s10911-018-9419-x. No abstract available.

PMID:
30406903
2.

Beyond DNA: the Role of Epigenetics in the Premalignant Progression of Breast Cancer.

DeVaux RS, Herschkowitz JI.

J Mammary Gland Biol Neoplasia. 2018 Dec;23(4):223-235. doi: 10.1007/s10911-018-9414-2. Epub 2018 Oct 10. Review.

3.

Surface-enhanced Raman scattering investigation of targeted delivery and controlled release of gemcitabine.

Santiago T, DeVaux RS, Kurzatkowska K, Espinal R, Herschkowitz JI, Hepel M.

Int J Nanomedicine. 2017 Oct 24;12:7763-7776. doi: 10.2147/IJN.S149306. eCollection 2017.

4.

Inertial Microfluidic Cell Stretcher (iMCS): Fully Automated, High-Throughput, and Near Real-Time Cell Mechanotyping.

Deng Y, Davis SP, Yang F, Paulsen KS, Kumar M, Sinnott DeVaux R, Wang X, Conklin DS, Oberai A, Herschkowitz JI, Chung AJ.

Small. 2017 Jul;13(28). doi: 10.1002/smll.201700705. Epub 2017 May 23.

5.

Molecular and Cellular Changes in Breast Cancer and New Roles of lncRNAs in Breast Cancer Initiation and Progression.

Kumar M, DeVaux RS, Herschkowitz JI.

Prog Mol Biol Transl Sci. 2016;144:563-586. doi: 10.1016/bs.pmbts.2016.09.011. Epub 2016 Oct 20. Review.

PMID:
27865468
6.

Stand-Sit Microchip for High-Throughput, Multiplexed Analysis of Single Cancer Cells.

Ramirez L, Herschkowitz JI, Wang J.

Sci Rep. 2016 Sep 1;6:32505. doi: 10.1038/srep32505.

7.

Erratum: Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation.

Welte T, Kim IS, Tian L, Gao X, Wang H, Li J, Holdman XB, Herschkowitz JI, Pond A, Xie G, Kurley S, Nguyen T, Liao L, Dobrolecki LE, Pang L, Mo Q, Edwards DP, Huang S, Xin L, Xu J, Li Y, Lewis MT, Wang T, Westbrook TF, Rosen JM, Zhang XH.

Nat Cell Biol. 2016 Jun 28;18(7):822. doi: 10.1038/ncb3379. No abstract available.

PMID:
27350446
8.

Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation.

Welte T, Kim IS, Tian L, Gao X, Wang H, Li J, Holdman XB, Herschkowitz JI, Pond A, Xie G, Kurley S, Nguyen T, Liao L, Dobrolecki LE, Pang L, Mo Q, Edwards DP, Huang S, Xin L, Xu J, Li Y, Lewis MT, Wang T, Westbrook TF, Rosen JM, Zhang XH.

Nat Cell Biol. 2016 Jun;18(6):632-44. doi: 10.1038/ncb3355. Epub 2016 May 16. Erratum in: Nat Cell Biol. 2016 Jun 28;18(7):822.

9.

Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers.

Pfefferle AD, Agrawal YN, Koboldt DC, Kanchi KL, Herschkowitz JI, Mardis ER, Rosen JM, Perou CM.

Dis Model Mech. 2016 Jul 1;9(7):749-57. doi: 10.1242/dmm.025239. Epub 2016 May 5.

10.

Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.

Elsarraj HS, Hong Y, Valdez KE, Michaels W, Hook M, Smith WP, Chien J, Herschkowitz JI, Troester MA, Beck M, Inciardi M, Gatewood J, May L, Cusick T, McGinness M, Ricci L, Fan F, Tawfik O, Marks JR, Knapp JR, Yeh HW, Thomas P, Carrasco DR, Fields TA, Godwin AK, Behbod F.

Breast Cancer Res. 2015 Sep 17;17:128. doi: 10.1186/s13058-015-0630-z.

11.

BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development.

Bai F, Chan HL, Scott A, Smith MD, Fan C, Herschkowitz JI, Perou CM, Livingstone AS, Robbins DJ, Capobianco AJ, Pei XH.

Cancer Res. 2014 Nov 1;74(21):6161-72. doi: 10.1158/0008-5472.CAN-14-1119. Epub 2014 Sep 19.

12.

Overexpression of miR-146a in basal-like breast cancer cells confers enhanced tumorigenic potential in association with altered p53 status.

Sandhu R, Rein J, D'Arcy M, Herschkowitz JI, Hoadley KA, Troester MA.

Carcinogenesis. 2014 Nov;35(11):2567-75. doi: 10.1093/carcin/bgu175. Epub 2014 Aug 14.

13.

Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts.

Pfefferle AD, Herschkowitz JI, Usary J, Harrell JC, Spike BT, Adams JR, Torres-Arzayus MI, Brown M, Egan SE, Wahl GM, Rosen JM, Perou CM.

Genome Biol. 2013 Nov 12;14(11):R125. doi: 10.1186/gb-2013-14-11-r125.

14.

c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer.

Nair R, Roden DL, Teo WS, McFarland A, Junankar S, Ye S, Nguyen A, Yang J, Nikolic I, Hui M, Morey A, Shah J, Pfefferle AD, Usary J, Selinger C, Baker LA, Armstrong N, Cowley MJ, Naylor MJ, Ormandy CJ, Lakhani SR, Herschkowitz JI, Perou CM, Kaplan W, O'Toole SA, Swarbrick A.

Oncogene. 2014 Jul 24;33(30):3992-4002. doi: 10.1038/onc.2013.368. Epub 2013 Sep 23.

PMID:
24056965
15.

Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties.

Taube JH, Malouf GG, Lu E, Sphyris N, Vijay V, Ramachandran PP, Ueno KR, Gaur S, Nicoloso MS, Rossi S, Herschkowitz JI, Rosen JM, Issa JP, Calin GA, Chang JT, Mani SA.

Sci Rep. 2013;3:2687. doi: 10.1038/srep02687.

16.

Predicting drug responsiveness in human cancers using genetically engineered mice.

Usary J, Zhao W, Darr D, Roberts PJ, Liu M, Balletta L, Karginova O, Jordan J, Combest A, Bridges A, Prat A, Cheang MC, Herschkowitz JI, Rosen JM, Zamboni W, Sharpless NE, Perou CM.

Clin Cancer Res. 2013 Sep 1;19(17):4889-99. doi: 10.1158/1078-0432.CCR-13-0522. Epub 2013 Jun 18.

17.

Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer.

Knight JF, Lesurf R, Zhao H, Pinnaduwage D, Davis RR, Saleh SM, Zuo D, Naujokas MA, Chughtai N, Herschkowitz JI, Prat A, Mulligan AM, Muller WJ, Cardiff RD, Gregg JP, Andrulis IL, Hallett MT, Park M.

Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):E1301-10. doi: 10.1073/pnas.1210353110. Epub 2013 Mar 18.

18.

FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer.

Hollier BG, Tinnirello AA, Werden SJ, Evans KW, Taube JH, Sarkar TR, Sphyris N, Shariati M, Kumar SV, Battula VL, Herschkowitz JI, Guerra R, Chang JT, Miura N, Rosen JM, Mani SA.

Cancer Res. 2013 Mar 15;73(6):1981-92. doi: 10.1158/0008-5472.CAN-12-2962. Epub 2013 Feb 1.

19.

Noncoding RNAs involved in mammary gland development and tumorigenesis: there's a long way to go.

Shore AN, Herschkowitz JI, Rosen JM.

J Mammary Gland Biol Neoplasia. 2012 Mar;17(1):43-58. doi: 10.1007/s10911-012-9247-3. Epub 2012 Mar 9. Review.

20.

Mouse models of triple negative [basal-like/claudin low] breast cancer.

Herschkowitz JI, Lubet R.

Breast Dis. 2010;32(1-2):63-71. doi: 10.3233/BD-2010-0321. Review.

PMID:
21965308
21.

MicroRNAs add an additional layer to the complexity of cell signaling.

Herschkowitz JI, Fu X.

Sci Signal. 2011 Jul 26;4(184):jc5. doi: 10.1126/scisignal.2002182. Review.

PMID:
21868350
22.

Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells.

Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D, Knezevic J, Greene SB, Darr D, Troester MA, Hilsenbeck SG, Medina D, Perou CM, Rosen JM.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2778-83. doi: 10.1073/pnas.1018862108. Epub 2011 Jun 1.

23.

RB1 and p53 at the crossroad of EMT and triple-negative breast cancer.

Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE, Wang S, Herschkowitz JI, Egan SE, Perou CM, Zacksenhaus E.

Cell Cycle. 2011 May 15;10(10):1563-70. Epub 2011 May 15. Review.

PMID:
21502814
24.

The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo.

Meerbrey KL, Hu G, Kessler JD, Roarty K, Li MZ, Fang JE, Herschkowitz JI, Burrows AE, Ciccia A, Sun T, Schmitt EM, Bernardi RJ, Fu X, Bland CS, Cooper TA, Schiff R, Rosen JM, Westbrook TF, Elledge SJ.

Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3665-70. doi: 10.1073/pnas.1019736108. Epub 2011 Feb 9.

25.

MPA-induced gene expression and stromal and parenchymal gene expression profiles in luminal murine mammary carcinomas with different hormonal requirements.

Giulianelli S, Herschkowitz JI, Patel V, Lamb CA, Gutkind JS, Molinolo A, Perou CM, Lanari C.

Breast Cancer Res Treat. 2011 Aug;129(1):49-67. doi: 10.1007/s10549-010-1185-4. Epub 2010 Oct 2.

PMID:
20890655
26.

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.

Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM.

Breast Cancer Res. 2010;12(5):R68. doi: 10.1186/bcr2635. Epub 2010 Sep 2.

27.

Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes.

Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, Hollier BG, Ram PT, Lander ES, Rosen JM, Weinberg RA, Mani SA.

Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15449-54. doi: 10.1073/pnas.1004900107. Epub 2010 Aug 16. Erratum in: Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):19132.

28.

Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status.

Jiang Z, Deng T, Jones R, Li H, Herschkowitz JI, Liu JC, Weigman VJ, Tsao MS, Lane TF, Perou CM, Zacksenhaus E.

J Clin Invest. 2010 Sep;120(9):3296-309. doi: 10.1172/JCI41490. Epub 2010 Aug 2.

29.

Small players with big roles: microRNAs as targets to inhibit breast cancer progression.

Greene SB, Herschkowitz JI, Rosen JM.

Curr Drug Targets. 2010 Sep;11(9):1059-73. Review.

30.

Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer.

Pond AC, Herschkowitz JI, Schwertfeger KL, Welm B, Zhang Y, York B, Cardiff RD, Hilsenbeck S, Perou CM, Creighton CJ, Lloyd RE, Rosen JM.

Cancer Res. 2010 Jun 15;70(12):4868-79. doi: 10.1158/0008-5472.CAN-09-4404. Epub 2010 May 25.

31.

The ups and downs of miR-205: identifying the roles of miR-205 in mammary gland development and breast cancer.

Greene SB, Herschkowitz JI, Rosen JM.

RNA Biol. 2010 May-Jun;7(3):300-4. Epub 2010 May 21. Review.

32.

Breast cancer stem cells: initiating a new sort of thinking.

Herschkowitz JI.

Dis Model Mech. 2010 May-Jun;3(5-6):257-8. doi: 10.1242/dmm.005207. No abstract available.

33.

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.

Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC.

Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13820-5. doi: 10.1073/pnas.0905718106. Epub 2009 Aug 3.

34.

The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas.

Herschkowitz JI, He X, Fan C, Perou CM.

Breast Cancer Res. 2008;10(5):R75. doi: 10.1186/bcr2142. Epub 2008 Sep 9.

35.

Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1.

Wright MH, Robles AI, Herschkowitz JI, Hollingshead MG, Anver MR, Perou CM, Varticovski L.

Mol Cancer. 2008 Apr 7;7:29. doi: 10.1186/1476-4598-7-29.

36.

ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex.

Li Z, Tognon CE, Godinho FJ, Yasaitis L, Hock H, Herschkowitz JI, Lannon CL, Cho E, Kim SJ, Bronson RT, Perou CM, Sorensen PH, Orkin SH.

Cancer Cell. 2007 Dec;12(6):542-58.

37.

Characterization of mammary tumors from Brg1 heterozygous mice.

Bultman SJ, Herschkowitz JI, Godfrey V, Gebuhr TC, Yaniv M, Perou CM, Magnuson T.

Oncogene. 2008 Jan 17;27(4):460-8. Epub 2007 Jul 16.

PMID:
17637742
38.

Clustering microarray-derived gene lists through implicit literature relationships.

Burkart MF, Wren JD, Herschkowitz JI, Perou CM, Garner HR.

Bioinformatics. 2007 Aug 1;23(15):1995-2003. Epub 2007 May 30.

PMID:
17537751
39.

Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.

Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CM.

Genome Biol. 2007;8(5):R76.

40.

Gene expression patterns associated with p53 status in breast cancer.

Troester MA, Herschkowitz JI, Oh DS, He X, Hoadley KA, Barbier CS, Perou CM.

BMC Cancer. 2006 Dec 6;6:276.

Supplemental Content

Loading ...
Support Center